Reata Pharmaceuticals Alpha and Beta Analysis
| RETADelisted Stock | USD 109.67 3.31 2.93% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Reata Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Reata Pharmaceuticals over a specified time horizon. Remember, high Reata Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Reata Pharmaceuticals' market risk premium analysis include:
Beta (0.13) | Alpha 0.21 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Reata |
Reata Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Reata Pharmaceuticals market risk premium is the additional return an investor will receive from holding Reata Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Reata Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Reata Pharmaceuticals' performance over market.| α | 0.21 | β | -0.13 |
Reata Pharmaceuticals Fundamentals Vs Peers
Comparing Reata Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Reata Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Reata Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Reata Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Reata Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Reata Pharmaceuticals to competition |
| Fundamentals | Reata Pharmaceuticals | Peer Average |
| Return On Equity | -1.12 | -0.31 |
| Return On Asset | -0.38 | -0.14 |
| Operating Margin | (14.55) % | (5.51) % |
| Current Valuation | 6.4 B | 16.62 B |
| Shares Outstanding | 33.59 M | 571.82 M |
| Shares Owned By Insiders | 4.10 % | 10.09 % |
| Shares Owned By Institutions | 88.46 % | 39.21 % |
Reata Pharmaceuticals Opportunities
Reata Pharmaceuticals Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | After Pfizer-Seagen deal, analysts expect more MA activity - FiercePharma | 05/09/2023 |
2 | The one-year returns have been splendid for Reata Pharmaceuticals shareholders despite underlying losses increasing | 06/07/2023 |
3 | TD Cowen starts Reata at outperform, cites sales potential of ataxia drug | 07/06/2023 |
About Reata Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Reata or other delisted stocks. Alpha measures the amount that position in Reata Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Reata Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Reata Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Reata Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Reata Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Reata Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Reata Pharmaceuticals' management manipulating its earnings.
| 14th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Reata Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |